Tag: dapagliflozin
-
NHS Urges Quick Action: See Your GP Now If You Have Three Dapagliflozin Symptoms
What is dapagliflozin and why NHS guidance matters Dapagliflozin is a medication commonly prescribed for type 2 diabetes and is also used to support people with heart failure or chronic kidney disease. While it can help manage blood sugar and protect organ function, it also carries potential side effects that require vigilance. The NHS has…
-
NHS Urges Immediate GPVisit: Dapagliflozin Warning If You Have Three Symptoms
What the NHS warning means fordapagliflozin users The NHS has issued a clear safety warning for people taking the diabetes drug dapagliflozin, which is also prescribed for heart failure and chronic kidney disease. The warning emphasizes that patients should contact their GP immediately if they experience any combination of three specific symptoms. While dapagliflozin offers…
-
NHS Urges GP Visit Now if You Have Three Symptoms While Taking Dapagliflozin
H2: What is dapagliflozin and who uses it? Dapagliflozin is a medication commonly prescribed to manage type 2 diabetes, helping the kidneys remove excess sugar through urine. It is also used in some patients with heart failure and chronic kidney disease to protect organ function and improve outcomes. While it can offer important benefits, it…
-
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
New Findings Question SGLT2 Inhibitors for Post-Ablation AF Recurrence In a development that surprises many in the cardiology community, the DARE-HF trial examined whether the SGLT2 inhibitor dapagliflozin could reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in patients who recently underwent ablation for AF, the study aimed to determine if adding…
-
DARE-AF: Dapagliflozin Fails to Reduce AF Recurrence After Catheter Ablation
Overview: DARE-AF Trial Questions SGLT2 Inhibition After Ablation The latest findings from the DARE-AF trial suggest that dapagliflozin, an SGLT2 inhibitor, does not reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in a diverse patient population, the study aimed to determine whether adding dapagliflozin to standard post-ablation care could lower AF recurrence…
-
DARE-AF Trial: Dapagliflozin Fails to Reduce AF Burden After Ablation
Overview: Aiming to Lower AF Recurrence With SGLT2 Inhibition The DARE-HF trial, conducted in New Orleans, tested whether dapagliflozin, an SGLT2 inhibitor, could reduce the burden of atrial fibrillation (AF) after catheter ablation. AF remains a leading heart rhythm disorder, and recurrence after ablation poses a persistent challenge for patients and clinicians. While SGLT2 inhibitors…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric Analysis (2012–2024)
Introduction Dapagliflozin, a leading SGLT2 inhibitor, has evolved from a glucose-lowering agent to a cornerstone therapy for heart failure (HF). Built on pivotal trials like DAPA-HF and DELIVER, dapagliflozin now targets a broad spectrum of HF patients, including those without diabetes. A recent bibliometric analysis of literature from 2012 to 2024 maps the global research…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric View (2012–2024)
Introduction: Dapagliflozin as a Cornerstone in Heart Failure Therapy Heart failure (HF) remains a global healthcare challenge with rising prevalence and substantial economic burden. Dapagliflozin, an SGLT2 inhibitor, emerged as a pivotal therapy beyond glucose control, driven by landmark trials such as DAPA-HF. A bibliometric analysis of research from 2012 to 2024 reveals how scientific…
-
Knowledge Gaps and Emerging Trends in Dapagliflozin for Heart Failure: A 2012–2024 Bibliometric Analysis
Introduction Dapagliflozin, a pioneering SGLT2 inhibitor, has evolved from a diabetes medication to a cornerstone therapy for heart failure (HF). Built on pivotal trials such as DAPA-HF and DELIVER, its role now spans reduced and preserved ejection fraction HF subtypes, with ongoing investigations into cardiorenal protection and fibrosis modulation. This article interprets a comprehensive bibliometric…